Jidinum (Sitagliptin)

Sitagliptin works by selectively blocking the enzyme dipeptidyl peptidase‑4 (DPP‑4), which normally degrades the incretin hormones GLP‑1 and GIP. Inhibition prolongs these hormones’ activity, leading to increased insulin secretion and reduced glucagon release in a glucose‑dependent manner, thereby lowering blood glucose.

The dosage of Jidinum is determined by the prescribing healthcare professional based on individual patient factors such as renal function, concomitant medications, and glycemic targets. The prescriber will select the appropriate strength and dosing schedule, and patients should follow the prescribed regimen without making changes on their own.

The safety of sitagliptin in pregnancy and lactation has not been fully established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider after careful assessment.

To request Jidinum, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with sulfonylureas, sitagliptin offers glucose‑dependent insulin stimulation, resulting in a lower risk of hypoglycemia. Unlike metformin, it does not affect gastrointestinal tolerance. As a DPP‑4 inhibitor, it provides an oral option with a distinct mechanism, often used as add‑on therapy when first‑line agents are insufficient.

Jidinum tablets should be stored at ambient temperature, below 25 °C, in their original packaging to protect from moisture and light. Keep the medication out of reach of children and do not use if the product appears discolored or damaged.

Jidinum is taken orally, usually once daily, with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water, and patients should adhere to the dosing schedule prescribed to maintain consistent blood glucose control.

The most serious adverse events linked to sitagliptin include acute pancreatitis, severe allergic reactions such as angioedema or Stevens‑Johnson syndrome, and rare cases of joint pain. Patients should seek immediate medical attention if they experience persistent abdominal pain, swelling of the face or throat, or unexplained arthralgia.

Jidinum is contraindicated in patients with a known hypersensitivity to sitagliptin or any component of the formulation. Caution is also advised for individuals with severe renal impairment, a history of pancreatitis, or those taking concomitant medications that may increase the risk of hypoglycemia.